(-)-Lupinine



Compound IDCDAMM01867
Common name(-)-Lupinine
IUPAC name2,3,4,6,7,8,9,9a-octahydro-1H-quinolizin-1-ylmethanol
Molecular formulaC10H19NO

Experimental data

Retention time1.4
Adduct[M+H]+
Actual mz170.154
Theoretical mz170.154
Error1.32
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.5644

Identifiers and class information

Inchi keyHDVAWXXJVMJBAR-NLJMKPLXNA-N
SmilesOCC1CCCN2CCCCC21
SuperclassAlkaloids and derivatives
ClassLupin alkaloids

Plant source

  • Curcuma longa L.

    • Pharmacokinetic properties

    Number of descriptor values(#stars)1
    Number of non-conjugated amine groups (#amine)1
    Number of amidine and guanidine groups (#amidine)0
    Number of carboxylic acid groups (#acid)0
    Number of non-conjugated amide groups (#amide)0
    Number of rotatable bonds (#rotor)2
    Number of reactive functional groups (#rtvFG)0
    Predicted central nervous system activity (CNS)1
    Molecular weight (mol_MW)169.266
    Computed dipole moment(dipole)2.349
    Total solvent accessible surface area (SASA)397.902
    Hydrophobic component of SASA (FOSA)345.313
    Hydrophilic component of SASA (FISA)52.589
    Pie component of the SASA (PISA)0
    Weakly polar component of the SASA (WPSA)0
    Total solvent accesible volume (volume)660.569
    Number of hydrogen bond donors (donorHB)1
    Number of hydrogen bond acceptors (accptHB)3.7
    Free energy of solvation of dipole (dip^2/V)0.0083531
    Index of cohesive interaction in solids (ACxDN^.5/SA)0.0092988
    Globularity descriptor (glob)0.921865
    Predicted polarizability in cubic angstroms (QPpolrz)18.998
    Predicted hexadecane/gas partition coefficient (QPlogPC16)5.199
    Predicted octanol/gas partition coefficient (QPlogPoct)8.849
    Predicted water/gas partition coefficient (QPlogPw)5.702
    Predicted octanol/water partition coefficient (QPlogPo/w)1.024
    Predicted aqueous solubility (QPlogS)-0.803
    Conformation-independent predicted aqueous solubility (CIQPlogS)-0.25
    Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-3.522
    Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)783.603
    Predicted brain/blood partition coefficient (QPlogBB)0.429
    Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)420.494
    Predicted skin permeability, log Kp (QPlogKp)-4.359
    PM3 calculated ionization potential (IP(ev))8.93
    PM3 calculated electron affinity (EA(eV))-2.429
    Number of likely metabolic reactions (#metab)1
    Prediction of binding to human serum albumin (QPlogKhsa)-0.32
    Predicted qualitative human oral absorption (HumanOralAbsorption)3
    Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)84.742
    Solvent-accessible surface area of fluorine atoms (SAFluorine)0
    Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
    Van der Waals surface area (PSA)27.925
    Number of nitrogen and oxygen atoms (#NandO)2
    Number of violations of Lipinski’s rule of five (RuleOfFive)0
    Number of violations of Jorgensen’s rule of three (RuleOfThree)0

    Compound-target network

    Cytoscape Graph

    Protein targets associated with phytocompound

    Uniprot ID Gene name Target name TTD_ID Prediction source
    P43681CHRNA4Neuronal acetylcholine receptor; alpha4/beta2T70967SwissTargetPrediction
    P06241FYNTyrosine-protein kinase FYNT17980SwissTargetPrediction
    P00533EGFREpidermal growth factor receptor erbB1T59328SwissTargetPrediction
    P11229CHRM1Muscarinic acetylcholine receptor M1T28893SwissTargetPrediction
    Q99720SIGMAR1Sigma opioid receptorT46360SwissTargetPrediction and SEA
    P21397MAOAMonoamine oxidase AT83875SwissTargetPrediction
    P11940PABPC1Polyadenylate-binding protein 1T58679SwissTargetPrediction
    Q15125EBPAnti-estrogen binding site (AEBS)T25317SwissTargetPrediction
    O00754MAN2B1Lysosomal alpha-mannosidaseT63156SwissTargetPrediction and SEA
    P06280GLAAlpha-galactosidase AT61339SwissTargetPrediction
    P14555PLA2G2APhospholipase A2 group IIAT19160SwissTargetPrediction
    P04054PLA2G1BPhospholipase A2 group 1BT31479SwissTargetPrediction
    P48449LSSLanosterol synthaseT56175SwissTargetPrediction
    P16278GLB1Beta-galactosidase (by homology)T73134SwissTargetPrediction
    Q16739UGCGCeramide glucosyltransferaseT14908SwissTargetPrediction
    O43451MGAMMaltase-glucoamylaseT92777SwissTargetPrediction
    P10253GAALysosomal alpha-glucosidase (by homology)T31514SwissTargetPrediction
    P06280GLAAlpha-galactosidase AT61339SwissTargetPrediction
    P06280GLAAlpha-galactosidase AT61339SwissTargetPrediction
    P27338MAOBMonoamine oxidase BT83011SwissTargetPrediction
    Q01959SLC6A3Dopamine transporterT55959SwissTargetPrediction
    P23975SLC6A2Norepinephrine transporterT21945SwissTargetPrediction
    P08172CHRM2Muscarinic acetylcholine receptor M2T46185SwissTargetPrediction
    P04062GBABeta-glucocerebrosidaseT84173SwissTargetPrediction
    P30926CHRNB4Neuronal acetylcholine receptor; alpha2/beta4T73724SwissTargetPrediction

    Target associated diseases

    TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
    T70967DI0029Aneurysm/dissection[ICD-11: BD50]P43681CHRNA4
    T70967DI0191Hypertensive crisis[ICD-11: BA03]P43681CHRNA4
    T70967DI0196Hypotension[ICD-11: BA20-BA21]P43681CHRNA4
    T17980DI0286Myeloproliferative neoplasm[ICD-11: 2A20]P06241FYN
    T59328DI0030Angina pectoris[ICD-11: BA40]P00533EGFR
    T59328DI0062Breast cancer[ICD-11: 2C60-2C6Y]P00533EGFR
    T59328DI0095Colorectal cancer[ICD-11: 2B91]P00533EGFR
    T59328DI0121Diabetic foot ulcer[ICD-11: BD54]P00533EGFR
    T59328DI0220Ischemia[ICD-11: 8B10-8B11]P00533EGFR
    T59328DI0238Lung cancer[ICD-11: 2C25]P00533EGFR
    T59328DI0303Non-small-cell lung cancer[ICD-11: 2C25]P00533EGFR
    T59328DI0361Renal cell carcinoma[ICD-11: 2C90]P00533EGFR
    T59328DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P00533EGFR
    T59328DI0420Unspecific body region injury[ICD-11: ND56]P00533EGFR
    T28893DI0001Abdominal pelvic pain[ICD-11: MD81]P11229CHRM1
    T28893DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P11229CHRM1
    T28893DI0101Corneal disease[ICD-11: 9A76-9A78]P11229CHRM1
    T28893DI0129Dystonic disorder[ICD-11: 8A02]P11229CHRM1
    T28893DI0154Functional bladder disorder[ICD-11: GC50]P11229CHRM1
    T28893DI0157Gastric ulcer[ICD-11: DA60]P11229CHRM1
    T28893DI0166Glaucoma[ICD-11: 9C61]P11229CHRM1
    T28893DI0186Hyperhidrosis[ICD-11: EE00]P11229CHRM1
    T28893DI0218Irritable bowel syndrome[ICD-11: DD91]P11229CHRM1
    T28893DI0331Parkinsonism[ICD-11: 8A00]P11229CHRM1
    T28893DI0333Peptic ulcer[ICD-11: DA61]P11229CHRM1
    T28893DI0371Sebaceous gland disorder[ICD-11: ED91]P11229CHRM1
    T46360DI0105Cough[ICD-11: MD12]Q99720SIGMAR1
    T83875DI0117Depression[ICD-11: 6A70-6A7Z]P21397MAOA
    T83875DI0331Parkinsonism[ICD-11: 8A00]P21397MAOA
    T58679DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P11940PABPC1
    T25317DI0366Rheumatoid arthritis[ICD-11: FA20]Q15125EBP
    T63156DI0242Lysosomal disease[ICD-11: 5C56]O00754MAN2B1
    T61339DI0201Inborn carbohydrate metabolism error[ICD-11: 5C51]P06280GLA
    T19160DI0062Breast cancer[ICD-11: 2C60-2C6Y]P14555PLA2G2A
    T31479DI0230Leishmaniasis[ICD-11: 1F54]P04054PLA2G1B
    T31479DI0335Peroxisomal disease[ICD-11: 5C57]P04054PLA2G1B
    T31479DI0367Rosacea[ICD-11: ED90]P04054PLA2G1B
    T31479DI0398Synthesis disorder[ICD-11: 5C52-5C59]P04054PLA2G1B
    T56175DI0035Arterial occlusive disease[ICD-11: BD40]P48449LSS
    T73134DI0242Lysosomal disease[ICD-11: 5C56]P16278GLB1
    T14908DI0242Lysosomal disease[ICD-11: 5C56]Q16739UGCG
    T14908DI0257Metabolic disorder[ICD-11: 5C50-5D2Z]Q16739UGCG
    T92777DI0009Acute diabete complication[ICD-11: 5A2Y]O43451MGAM
    T92777DI0201Inborn carbohydrate metabolism error[ICD-11: 5C51]O43451MGAM
    T31514DI0201Inborn carbohydrate metabolism error[ICD-11: 5C51]P10253GAA
    T61339DI0201Inborn carbohydrate metabolism error[ICD-11: 5C51]P06280GLA
    T61339DI0201Inborn carbohydrate metabolism error[ICD-11: 5C51]P06280GLA
    T83011DI0115Dementia[ICD-11: 6D80-6D8Z]P27338MAOB
    T83011DI0117Depression[ICD-11: 6A70-6A7Z]P27338MAOB
    T83011DI0190Hypertension[ICD-11: BA00-BA04]P27338MAOB
    T83011DI0243Malaria[ICD-11: 1F40-1F45]P27338MAOB
    T83011DI0264Migraine[ICD-11: 8A80]P27338MAOB
    T83011DI0331Parkinsonism[ICD-11: 8A00]P27338MAOB
    T55959DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]Q01959SLC6A3
    T55959DI0051Bipolar disorder[ICD-11: 6A60]Q01959SLC6A3
    T55959DI0101Corneal disease[ICD-11: 9A76-9A78]Q01959SLC6A3
    T55959DI0290Narcolepsy[ICD-11: 7A20]Q01959SLC6A3
    T55959DI0308Obesity[ICD-11: 5B80-5B81]Q01959SLC6A3
    T55959DI0331Parkinsonism[ICD-11: 8A00]Q01959SLC6A3
    T21945DI0013Acute pain[ICD-11: MG31]P23975SLC6A2
    T21945DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]P23975SLC6A2
    T21945DI0087Chronic pain[ICD-11: MG30]P23975SLC6A2
    T21945DI0101Corneal disease[ICD-11: 9A76-9A78]P23975SLC6A2
    T21945DI0117Depression[ICD-11: 6A70-6A7Z]P23975SLC6A2
    T21945DI0166Glaucoma[ICD-11: 9C61]P23975SLC6A2
    T21945DI0264Migraine[ICD-11: 8A80]P23975SLC6A2
    T21945DI0301Nicotine use disorder[ICD-11: 6C4A]P23975SLC6A2
    T21945DI0308Obesity[ICD-11: 5B80-5B81]P23975SLC6A2
    T21945DI0324Pain[ICD-11: MG30-MG3Z]P23975SLC6A2
    T21945DI0395Stomach cancer[ICD-11: 2B72]P23975SLC6A2
    T46185DI0037Asthma[ICD-11: CA23]P08172CHRM2
    T46185DI0166Glaucoma[ICD-11: 9C61]P08172CHRM2
    T46185DI0278Muscle disorder[ICD-11: FB32-FB3Z]P08172CHRM2
    T46185DI0333Peptic ulcer[ICD-11: DA61]P08172CHRM2
    T46185DI0362Respiratory system disease[ICD-11: CB40-CB7Z]P08172CHRM2
    T46185DI0371Sebaceous gland disorder[ICD-11: ED91]P08172CHRM2
    T84173DI0257Metabolic disorder[ICD-11: 5C50-5D2Z]P04062GBA
    T73724DI0301Nicotine use disorder[ICD-11: 6C4A]P30926CHRNB4

    Copyright © 2025